drugset
drugset / Trial / NCT03118947

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

NCT03118947 ↗

Phase 2 Completed 79 enrolled ACADIA Pharmaceuticals Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of pimavanserin over 52 weeks of treatment in subjects with probable AD who have symptoms of agitation and aggression

Timeline

Start
2017-02-23
Primary completion
2019-02-25
Completion
2019-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimavanserin Small molecule 20 mg Oral
Subject Pimavanserin Small molecule 34 mg Oral

Indications

No indication recorded.